Compare Citius Pharmaceuticals Inc (CTXR) vs Upstart Holdings Inc (UPST) Price & Performance

CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.

Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.

UPST trades at $31.46, down 3.91% on the day, reflecting recent volatility amid mixed earnings. The stock shows a bearish technical trend with support near $29, while fundamentals highlight a return to profitability in 2025 with $1.02B revenue and $53.60M net income. Recent news emphasizes AI lending growth and a key $600M funding deal with Neuberger Berman, though margin pressures persist.

The outlook hinges on execution of AI-driven lending expansion and funding stability, with a consensus price target of $42.00 suggesting 33% upside. Risks include earnings volatility, high debt levels, and competitive fintech pressures. Analyst sentiment is balanced with 45% buy ratings, but investors await Q2 2026 results on August 4 for confirmation of growth trajectory.